Ambrx Biopharma Inc (DELISTED) (AMAM:DL)
27.99
+0.01
(+0.04%)
USD |
NASDAQ |
Mar 06, 16:00
28.00
+0.01
(+0.04%)
After-Hours: 20:00
Ambrx Biopharma Research and Development Expense (Quarterly): 16.27M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 16.27M |
| June 30, 2023 | 14.39M |
| March 31, 2023 | 9.75M |
| December 31, 2022 | 8.098M |
| Date | Value |
|---|---|
| September 30, 2022 | 12.44M |
| June 30, 2022 | 18.06M |
| March 31, 2022 | 14.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.098M
Minimum
Dec 2022
18.06M
Maximum
Jun 2022
13.39M
Average
14.39M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 3.542B |
| Axonics Inc | 11.06M |
| Harpoon Therapeutics Inc (DELISTED) | 12.32M |
| Merck & Co Inc | 3.992B |
| RayzeBio inc (DELISTED) | 18.17M |